Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808261 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept (POC) in Patients With Ischaemic Stroke
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT01808261: Clinical Trial Phase 2 study, sponsored by GlaxoSmithKline.
NCT01808261 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 134 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01808261, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients.
Primary Outcome
Gait is the way or manner in which a person walks. Gait velocity (walking speed) is an objective, quantitative measure of lower extremity motor recovery in individuals who have had a stroke. Participants were asked to walk at their usual pace over a level, indoor 10 meter (m) distance and were allowed to use their normal assistive devices. The time (seconds\[s\]) taken by the participants to travel the 10 m distance was recorded. Gait velocity (m/s) as assessed by study personnel was derived as:
Interventions
- DRUG Placebo
- DRUG GSK249320 100/mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2013-05-18 |
| Est. Completion | 2014-07-28 |
| Phase | Phase 2 |
Why NCT01808261 stopped before completion
NCT01808261 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01808261 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01808261 about?
NCT01808261 is a clinical study titled "Proof of Concept (POC) in Patients With Ischaemic Stroke". Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients.
What is the current status of trial NCT01808261?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2013-05-18. Estimated completion is 2014-07-28.
What interventions are being tested in trial NCT01808261?
The interventions under investigation include: Placebo (DRUG), GSK249320 100/mg (DRUG).
Who is sponsoring clinical trial NCT01808261?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01808261's enrollment target sits among peer trials
134 537th of 2000 higher than 1,463 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI